12/22
04:42 pm
mrk
SCHD vs. NOBL: Different Paths to Dividend Stability [Yahoo! Finance]
Low
Report
SCHD vs. NOBL: Different Paths to Dividend Stability [Yahoo! Finance]
12/22
12:46 pm
mrk
“Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer [Yahoo! Finance]
Low
Report
“Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer [Yahoo! Finance]
12/22
11:03 am
mrk
Radiopharmaceutical specialist Aktis seeks an IPO [Yahoo! Finance]
Low
Report
Radiopharmaceutical specialist Aktis seeks an IPO [Yahoo! Finance]
12/22
12:22 am
mrk
SCHD vs. VYM: A Higher Yield Or High Total Return Potential [Yahoo! Finance]
Medium
Report
SCHD vs. VYM: A Higher Yield Or High Total Return Potential [Yahoo! Finance]
12/21
09:40 pm
mrk
SCHD Offers a Higher Yield While FDVV Grows Faster [Yahoo! Finance]
Medium
Report
SCHD Offers a Higher Yield While FDVV Grows Faster [Yahoo! Finance]
12/21
12:49 pm
mrk
The Best Dividend ETF to Buy: SCHD Pays a High Yield While VIG Focuses on Dividend Growth [Yahoo! Finance]
Medium
Report
The Best Dividend ETF to Buy: SCHD Pays a High Yield While VIG Focuses on Dividend Growth [Yahoo! Finance]
12/20
09:41 pm
mrk
Dividend ETF Matchup: SCHD Offers Higher Yield While VIG Leads in Growth [Yahoo! Finance]
Medium
Report
Dividend ETF Matchup: SCHD Offers Higher Yield While VIG Leads in Growth [Yahoo! Finance]
12/19
03:17 pm
mrk
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans [Yahoo! Finance]
Low
Report
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans [Yahoo! Finance]
12/19
02:39 pm
mrk
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
Low
Report
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
12/19
10:04 am
mrk
Merck (MRK)'s CEO Has a “Better Hand,” Says Jim Cramer [Yahoo! Finance]
Low
Report
Merck (MRK)'s CEO Has a “Better Hand,” Says Jim Cramer [Yahoo! Finance]
12/18
10:49 pm
mrk
Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case [Seeking Alpha]
Low
Report
Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case [Seeking Alpha]
12/18
08:05 am
mrk
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $130.00 price target on the stock, up previously from $82.00.
Low
Report
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $130.00 price target on the stock, up previously from $82.00.
12/17
07:26 am
mrk
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck's Keytruda [Seeking Alpha]
Low
Report
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck's Keytruda [Seeking Alpha]
12/17
07:10 am
mrk
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery [Yahoo! Fina
Low
Report
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery [Yahoo! Fina
12/17
06:45 am
mrk
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
Low
Report
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
12/16
12:41 pm
mrk
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? [Yahoo! Finance]
Low
Report
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? [Yahoo! Finance]
12/16
07:48 am
mrk
Here's How Many Shares of SCHD You'd Need for $1,000 in Yearly Dividends [Yahoo! Finance]
Low
Report
Here's How Many Shares of SCHD You'd Need for $1,000 in Yearly Dividends [Yahoo! Finance]
12/15
08:23 am
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Bank of America Corporation from $105.00 to $120.00. They now have a "buy" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Bank of America Corporation from $105.00 to $120.00. They now have a "buy" rating on the stock.
12/15
06:40 am
mrk
Biotech Bill Bundled in Pentagon Spending Plan May Worsen Pharma's Patent Cliff Dilemma [Yahoo! Finance]
Low
Report
Biotech Bill Bundled in Pentagon Spending Plan May Worsen Pharma's Patent Cliff Dilemma [Yahoo! Finance]
12/14
08:41 am
mrk
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - SNS Insider [Yahoo! Finance]
Low
Report
Immuno-oncology Clinical Trials Market Projected to Reach USD 23.63 Billion by 2032 at a CAGR of 12.37% - SNS Insider [Yahoo! Finance]
12/12
07:05 pm
mrk
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE? [Yahoo! Finance]
Low
Report
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE? [Yahoo! Finance]
12/12
12:19 pm
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Morgan Stanley from $100.00 to $102.00. They now have an "equal weight" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Morgan Stanley from $100.00 to $102.00. They now have an "equal weight" rating on the stock.
12/12
08:45 am
mrk
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
Low
Report
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
12/11
07:38 am
mrk
Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1 [Yahoo! Finance]
Low
Report
Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1 [Yahoo! Finance]
12/10
11:40 am
mrk
Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104 [Yahoo! Finance]
Low
Report
Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104 [Yahoo! Finance]